Rhomboid Intercostal Block With Sub-Serratus Plane Block Versus Erector Spinae Block
RISS-ESPB
Analgesic Efficacy of Rhomboid Intercostal Block With Sub-Serratus Plane Block Versus Erector Spinae Block in Breast Cancer Surgery
1 other identifier
interventional
80
1 country
1
Brief Summary
This study compares two nerve block techniques-Rhomboid Intercostal with Sub-Serratus Plane Block versus Erector Spinae Plane Block-for pain relief after breast cancer surgery. It aims to determine which method provides better postoperative pain control, reduces opioid use, and improves recovery in patients undergoing modified radical mastectomy at the National Cancer Institute, Cairo University.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jun 2025
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2025
CompletedFirst Submitted
Initial submission to the registry
June 10, 2025
CompletedFirst Posted
Study publicly available on registry
June 27, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 1, 2026
June 27, 2025
June 1, 2025
1 year
June 10, 2025
June 25, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Postoperative Pain Scores
Postoperative pain will be assessed using the Visual Analog Scale (VAS) both at rest (static) and during movement (dynamic). Assessments will be conducted at 2, 6, 12, and 24 hours following surgery. The VAS is a 10-centimeter scale, where 0 indicates "no pain" and 10 indicates the "worst imaginable pain." Unit of Measure: VAS score (0-10)
First 24 hours postoperatively
Total Opioid Consumption
The total amount of opioid analgesics administered within the first 24 postoperative hours will be recorded for each patient. All opioid dosages will be converted to intravenous morphine equivalents for standardization. Unit of Measure: Milligrams of intravenous morphine equivalents (mg)
First 24 hours postoperatively
Study Arms (2)
Rhomboid Intercostal Block with Sub-Serratus Plane Block
EXPERIMENTALParticipants in this group will receive ultrasound-guided Rhomboid Intercostal Block (20 mL of 0.25% bupivacaine between rhomboid major and intercostal space) followed by Sub-Serratus Plane Block (20 mL of 0.25% bupivacaine between serratus anterior and ribs) 30-45 minutes before general anesthesia for Modified Radical Mastectomy.
Erector Spinae Plane Block
ACTIVE COMPARATORParticipants in this group will receive an ultrasound-guided Erector Spinae Plane Block with 30 mL of 0.25% bupivacaine injected into the paraspinal plane at the T4-T5 level, 30-45 minutes prior to general anesthesia for Modified Radical Mastectomy.
Interventions
Ultrasound-guided regional anesthesia combining two injections: Rhomboid Intercostal Block (20 mL of 0.25% bupivacaine injected between rhomboid major and intercostal space) Sub-Serratus Plane Block (20 mL of 0.25% bupivacaine injected between serratus anterior and ribs). Both performed 30-45 minutes before Modified Radical Mastectomy under general anesthesia.
Ultrasound-guided regional block with 30 mL of 0.25% bupivacaine injected into the paraspinal plane at the T4-T5 level, between the erector spinae muscle and the transverse processes. Performed 30-45 minutes prior to general anesthesia for Modified Radical Mastectomy.
Eligibility Criteria
You may qualify if:
- Female breast cancer patients undergoing Modified Radical Mastectomy (MRM)
- ASA physical status II or III
- Age between 18 and 65 years
- Body Mass Index (BMI) \> 20 kg/m² and \< 35 kg/m²
You may not qualify if:
- Patient refusal
- ASA physical status IV
- Age \<18 years or \>65 years
- BMI \< 20 kg/m² or \> 35 kg/m²
- Known allergy or contraindication to local anesthetics or opioids
- History of psychological disorders or chronic pain
- Contraindications to regional anesthesia (e.g., coagulopathy, local infection, peripheral neuropathy)
- Severe respiratory, cardiac, hepatic, or renal disease
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Cairo Universitylead
Study Sites (1)
National Cancer Institute - Cairo University
Cairo, Egypt
Related Links
Study Officials
- PRINCIPAL INVESTIGATOR
Sayed Mahmoud M Abed, MD
National Cancer Institute - Cairo University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Masking Details
- Double-blind design: Participants, anesthesia providers, investigators, and outcome assessors will be blinded to group allocation. Group assignments will be concealed using opaque sealed envelopes, and blocks will be performed by anesthesiologists not involved in intraoperative care or postoperative evaluation.
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- assistant professor
Study Record Dates
First Submitted
June 10, 2025
First Posted
June 27, 2025
Study Start
June 1, 2025
Primary Completion (Estimated)
June 1, 2026
Study Completion (Estimated)
July 1, 2026
Last Updated
June 27, 2025
Record last verified: 2025-06
Data Sharing
- IPD Sharing
- Will not share
Individual Participant Data (IPD) will not be shared due to institutional policies regarding data confidentiality and privacy. Additionally, there is no established infrastructure for secure data sharing or monitoring of secondary data use at this time.